[
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=d005d980aaecec449da471845785f49fbddea8ee079b348c88bf358b9db725c4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738342800,
      "headline": "Health Care Roundup: Market Talk",
      "id": 132521690,
      "image": "",
      "related": "ABBV",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=d005d980aaecec449da471845785f49fbddea8ee079b348c88bf358b9db725c4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats",
    "summary": "AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=52ea6d1eb9485f535cda63646063a18e73fea5a4bf5adc411aa4517021e85af9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738341550,
      "headline": "AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats",
      "id": 132506608,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=52ea6d1eb9485f535cda63646063a18e73fea5a4bf5adc411aa4517021e85af9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate",
    "summary": "AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate",
    "url": "https://finnhub.io/api/news?id=4a889560e3383124a4c22de47cb2dfd1fd918e312fd14c2d98f716d521b040fa",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738339881,
      "headline": "AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate",
      "id": 132521691,
      "image": "",
      "related": "ABBV",
      "source": "DowJones",
      "summary": "AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate",
      "url": "https://finnhub.io/api/news?id=4a889560e3383124a4c22de47cb2dfd1fd918e312fd14c2d98f716d521b040fa"
    }
  },
  {
    "ts": null,
    "headline": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
    "summary": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
    "url": "https://finnhub.io/api/news?id=b0d5315e4d5c12507ecf204667f73122509f5d6223198730d54f50c14f946dc2",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738339270,
      "headline": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
      "id": 132521692,
      "image": "",
      "related": "ABBV",
      "source": "DowJones",
      "summary": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
      "url": "https://finnhub.io/api/news?id=b0d5315e4d5c12507ecf204667f73122509f5d6223198730d54f50c14f946dc2"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds",
    "summary": "Analysis of AbbVie Inc.'s Q4 2024 results, 2025 guidance, and future growth prospects, including the impact of clinical trial failures. Click for this ABBV update.",
    "url": "https://finnhub.io/api/news?id=19cfc102fd210e8941fca737c6b63c6c570976dca267ac75b30cc3bff54e5307",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738335143,
      "headline": "AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds",
      "id": 132506264,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157571110/image_2157571110.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Analysis of AbbVie Inc.'s Q4 2024 results, 2025 guidance, and future growth prospects, including the impact of clinical trial failures. Click for this ABBV update.",
      "url": "https://finnhub.io/api/news?id=19cfc102fd210e8941fca737c6b63c6c570976dca267ac75b30cc3bff54e5307"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript",
    "summary": "AbbVie Inc. (NYSE:ABBV) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ETCompany ParticipantsLiz Shea - Senior Vice President, Investor...",
    "url": "https://finnhub.io/api/news?id=c6916270944b505960241e46dafe8e973d102bf0896ed8ef58bd5c9ff36e76f3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738326366,
      "headline": "AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript",
      "id": 132505764,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ETCompany ParticipantsLiz Shea - Senior Vice President, Investor...",
      "url": "https://finnhub.io/api/news?id=c6916270944b505960241e46dafe8e973d102bf0896ed8ef58bd5c9ff36e76f3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%",
    "summary": "AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%",
    "url": "https://finnhub.io/api/news?id=2299b173da6c3cd89f800a6ef90451cf2a07da98ced0815163713cf7fa6a9b6d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738321020,
      "headline": "AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%",
      "id": 132521711,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%",
      "url": "https://finnhub.io/api/news?id=2299b173da6c3cd89f800a6ef90451cf2a07da98ced0815163713cf7fa6a9b6d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Jumps on Earnings and Revenue Beat",
    "summary": "AbbVie Stock Jumps on Earnings and Revenue Beat",
    "url": "https://finnhub.io/api/news?id=8863b11c7f9e394aabeaa49332e3a702fd25430f7e6aebf71447a605a81d2afb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738320600,
      "headline": "AbbVie Stock Jumps on Earnings and Revenue Beat",
      "id": 132521712,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Stock Jumps on Earnings and Revenue Beat",
      "url": "https://finnhub.io/api/news?id=8863b11c7f9e394aabeaa49332e3a702fd25430f7e6aebf71447a605a81d2afb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie : Reports Full Year and Fourth Quarter 2024 Financial Results",
    "summary": "PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results Reports Full-Year Diluted EPS of $2.39 on a GAAP...",
    "url": "https://finnhub.io/api/news?id=52852e591a0b7a3c1253680f4dd33fe44ce04731ebdd9c513e4c7a9332219037",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738313596,
      "headline": "AbbVie : Reports Full Year and Fourth Quarter 2024 Financial Results",
      "id": 132504790,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results Reports Full-Year Diluted EPS of $2.39 on a GAAP...",
      "url": "https://finnhub.io/api/news?id=52852e591a0b7a3c1253680f4dd33fe44ce04731ebdd9c513e4c7a9332219037"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges",
    "summary": "By Denny Jacob AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing...",
    "url": "https://finnhub.io/api/news?id=638ac5da30afc9cc893345a138d3a71a508618724dc5dc32c7c745a556afea8b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738312167,
      "headline": "AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges",
      "id": 132504676,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Denny Jacob AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing...",
      "url": "https://finnhub.io/api/news?id=638ac5da30afc9cc893345a138d3a71a508618724dc5dc32c7c745a556afea8b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: EPS down nearly 23% in Q4",
    "summary": "AbbVie reports adjusted EPS of $2.16 for the final quarter of 2024, down almost 23% year-on-year, despite sales of $15.1 billion, up 5.6% on a reported basis.On an operational basis - i.e., excluding...",
    "url": "https://finnhub.io/api/news?id=fac19963834cc2da854505d20b377240bd5ebc35ed70b8d72fd68f7851b2a871",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738311134,
      "headline": "AbbVie: EPS down nearly 23% in Q4",
      "id": 132504592,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie reports adjusted EPS of $2.16 for the final quarter of 2024, down almost 23% year-on-year, despite sales of $15.1 billion, up 5.6% on a reported basis.On an operational basis - i.e., excluding...",
      "url": "https://finnhub.io/api/news?id=fac19963834cc2da854505d20b377240bd5ebc35ed70b8d72fd68f7851b2a871"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Q4 Earnings Snapshot",
    "summary": "NORTH CHICAGO, Ill. — NORTH CHICAGO, Ill. — AbbVie Inc. on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier. On a per-share...",
    "url": "https://finnhub.io/api/news?id=642711de02e7e4071191131bc5ea529b9d3d7a3d2b6a061ba7844ace18af6581",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738309506,
      "headline": "AbbVie: Q4 Earnings Snapshot",
      "id": 132504416,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO, Ill. — NORTH CHICAGO, Ill. — AbbVie Inc. on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier. On a per-share...",
      "url": "https://finnhub.io/api/news?id=642711de02e7e4071191131bc5ea529b9d3d7a3d2b6a061ba7844ace18af6581"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs",
    "summary": "AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid...",
    "url": "https://finnhub.io/api/news?id=352a77e7d436c6ff83535f68fd2b935d5d073ec8b4d41b94523e10b366ef84af",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738309223,
      "headline": "AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs",
      "id": 132504410,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid...",
      "url": "https://finnhub.io/api/news?id=352a77e7d436c6ff83535f68fd2b935d5d073ec8b4d41b94523e10b366ef84af"
    }
  }
]